Candida albicans cells have the ability to form biofilms on biotic and abiotic surfaces, such as indwelling medical devices. C. albicans cells can interconvert between budded and hyphal growth forms, herein termed the budded-to-hyphal transition (BHT), which is important for the formation of mature biofilms. Previous work identified 23 small organic molecules that could inhibit the BHT but did not affect C. albicans cell viability or budded cell growth. These BHT inhibitors were proposed to inhibit multiple signalling pathways regulating the BHT, many of which also regulate biofilm formation. However, only three of the BHT inhibitors, buhytrinA, ETYA and CGP-37157, were capable of inhibiting in vitro biofilm formation of wild-type laboratory C. albicans strains. When clinical C. albicans isolates were examined for their ability to form biofilms, only 11 of the 28 clinical isolates tested (39 %) were capable of forming biofilms. Although buhytrinA, ETYA and CGP-37157 could inhibit the BHT of all 28 clinical isolates, they were only able to inhibit biofilm formation of a subset of these clinical isolates, with ETYA having 100 % efficacy. These data indicate that the biofilm-forming capability of laboratory and clinical isolates of C. albicans, as well as the efficacy of BHT inhibitors against these different isolates, can differ dramatically. These differences between laboratory and clinical isolates should be an important aspect to consider when examining potentially new antifungal therapeutics.
INTRODUCTION
The pathogenic yeast Candida albicans is a significant cause of morbidity and mortality in immunocompromised patients, primarily through its ability to grow and form biofilms on biotic surfaces and abiotic indwelling medical devices (Kojic & Darouiche, 2004; Lynch & Robertson, 2008) . C. albicans cells can colonize the mucosa and many different body organs, and can also disseminate throughout the body via the bloodstream, leading to systemic infections, septicaemia and potentially death (Mitchell, 1998; Pfaller & Diekema, 2007) . C. albicans cells also have the ability to form homogeneous or mixed biofilms on body tissues and on indwelling medical devices such as catheters, intravenous tubing, dentures, prostheses and contact lenses (Blankenship & Mitchell, 2006; ten Cate et al., 2009) . These biofilms are difficult to eliminate because C. albicans cells within biofilms have a higher degree of resistance to antifungal drugs (d 'Enfert, 2006) . Because of this increased antifungal drug resistance, persistent infection of indwelling medical devices usually forces the removal of the device from the body, potentially causing further complications and infection (Lynch & Robertson, 2008) .
C. albicans is a polymorphic fungus, growing either as budded cells or in a filamentous form as either pseudohyphal or true hyphal cells. The ability of C. albicans cells to switch between the budded and hyphal states, herein called the budded-to-hyphal transition (BHT), plays an important role in virulence and in biofilm formation (Ramage et al., 2002; Blankenship & Mitchell, 2006; Nobile & Mitchell, 2006; ten Cate et al., 2009) . This ability to exist in different cell states also allows C. albicans cells to adapt to many different environmental conditions, such as high temperature, nutrient deprivation and change in pH (Brown & Gow, 1999) . In response to these different environmental signals, the BHT and biofilm processes are tightly regulated by numerous cell signalling pathways (Brown, 2002; Biswas et al., 2007) .
We have previously identified 23 small molecules that block the BHT without affecting C. albicans cell viability or budded cell growth (Toenjes et al., 2005 (Toenjes et al., , 2009 . The ability of 17 of these BHT inhibitors to inhibit biofilm formation on the abiotic surface of polystyrene microplates was examined. We also examined the ability of 28 clinical C. albicans isolates to undergo the BHT and form biofilms. Interestingly, these clinical isolates had variable abilities to undergo the BHT and form biofilms, and only one small molecule was able to consistently block biofilm formation by the clinical isolates.
These data suggest that the ability of BHT inhibitors to block the BHT and biofilm formation of laboratory wild-type strains may not be a good indicator of their clinical efficacy against C. albicans strains isolated from patients.
METHODS
C. albicans strains, materials and media. Protocols for the growth and maintenance of laboratory C. albicans strains were previously described (Toenjes et al., 2005 (Toenjes et al., , 2009 ). Both laboratory and clinical C. albicans strains were grown on either rich medium YEPD (Sherman et al., 1986) or YNB medium (0.67 % yeast nitrogenous base, 2 % glucose and the required supplements of uridine, histidine and arginine, pH 7) to prevent hyphae and pseudohyphae formation. Growth in nutrientlimiting Spider medium (Liu et al., 1994) was used to induce hyphal growth at 37 uC, as previously described (Toenjes et al., 2005 (Toenjes et al., , 2009 ).
The laboratory C. albicans strains used in this study were BWP17 (ura3 : : imm434/ura3 : : imm434 iro1/iro1 : : imm434 his1 : : hisG/his1 : : hisG arg4/arg4) (Wilson et al., 1999) and CJN459 (ura3D : : limm434/ura3D : : limm434 arg4 : : hisG/arg4 : : hisG his1 : : hisG/his1 : : hisG bcr1 : : Tn7-UAU1/bcr1 : : Tn7-URA3) (Nobile & Mitchell, 2005) ; both kindly provided by Aaron Mitchell, Carnegie Mellon University. BWP17 is a biofilm-positive control and CJN459 is a biofilm-negative control due to the deletion of the Bcr1 transcription factor (Nobile & Mitchell, 2005; Nobile et al., 2006) . A total of 28 C. albicans clinical isolates were obtained from patients at the Fletcher Allen Health Care Microbiology Laboratory in Burlington, VT, USA (kindly provided by Courtney Scott and Washington Winn). All patient information regarding the sources of these clinical C. albicans isolates was purposefully not obtained.
Previously identified small-molecule BHT inhibitors (Toenjes et al., 2005 (Toenjes et al., , 2009 were obtained from commercial sources, dissolved in DMSO, and used at a final concentration of 100 mM, unless otherwise stated in the text. It should be noted that the previously identified BHT inhibitor 5762974 (Toenjes et al., 2005) , purchased from Chembridge, has been renamed buhytrinA (for budded-to-hyphal transition inhibitor A).
BHT assay. Quantification methods for the BHT assay were adapted from previous methods (Toenjes et al., 2005 (Toenjes et al., , 2009 ) with the following modifications. The cells were grown overnight in YEPD liquid medium and then transferred to YNB liquid medium for 6 h. Cells were then placed in hyphal-inducing Spider medium for at least 6 h instead of 4 h. After incubation in the Spider medium, 10 ml of the liquid cultures was placed on microscopy slides and the percentage of hyphal cells was quantified from photomicrographs (n ¢100 cells). The results were a mean of at least three independent assays.
Microplate-based biofilm assay. An adaptation of an established in vitro assay (Agarwal et al., 2008; Chandra et al., 2008) was used to examine the biofilm-forming capabilities of wild-type and clinical C. albicans strains. C. albicans cells from isolated single colonies were incubated in 5 ml YEPD medium for 14-15 h at 30 uC with shaking, resulting in .90 % budded cells. The cells were washed in sterile ddH 2 O, and 1610 5 cells, as determined by optical density, were diluted into liquid Spider medium. The liquid Spider cultures (0.5 ml) were inoculated into separate wells of a 48-well polystyrene microplate (Greiner Bio-One), and incubated at 37 uC for 48 h without shaking. Each well was then washed twice with 1 % PBS, dried and photographed. Biofilms were classified as positive (++), partial (+) or negative (2) (see Table 1 ).
When testing BHT inhibitors, the same biofilm assay was used, with the addition of 1.25 ml (100 mM) of the BHT inhibitor molecule in individual wells immediately after cells were added. The cells plus molecule were then incubated for 48 h at 37 uC without shaking. The molecules were classified as either inhibitors (+) or non-inhibitors (2) of biofilm formation (see Table 2 ).
Microscopy and photographic techniques. For the BHT assay, sample slides were viewed on a Nikon Eclipse E400 light microscope with a 610 objective and viewed through an XF100 filter. Images were obtained by using a Spot RT Monochrome camera and viewed with Spot Advanced software (Diagnostic Instruments). Photographs of microplates containing biofilms were obtained using a Sony Cybershot camera (DSC-S950 SteadyShot).
RESULTS AND DISCUSSION
Previous studies had identified 23 small organic molecules that could inhibit the BHT in carbon starvation Spider Table 1 . Biofilm formation and hyphae production of clinical C. albicans isolates For the biofilm assay, clinical C. albicans isolates were incubated in Spider medium within microplate wells for 48 h at 37 u C. Biofilms were classified as positive (++), partial (+) or negative (2) as in Fig. 1 . For % hyphae assay, the clinical isolates were incubated in Spider media for 6 h at 37 u C. Results are the mean of at least three independent assays.
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Biofilm formation % Hyphae A. Grald and others medium without affecting C. albicans cell viability or budded cell growth (Toenjes et al., 2005 (Toenjes et al., , 2009 . Spider medium has been used as a hyphal-inducing medium because the BHT inhibitors varied in their ability to block the BHT in response to growth in 10 % serum (Toenjes et al., 2005 (Toenjes et al., , 2009 , presumably due to molecule inactivation in the serum media. Seven of these BHT inhibitors were novel with no known cellular target (Toenjes et al., 2005) , whereas the remaining 16 BHT inhibitors had either known targets or biochemical activities in mammalian cells, many of which were involved in conserved cell signalling pathways (Toenjes et al., 2009) . Some of the signalling pathways that regulate the BHT also play a role in regulating biofilm formation (Nobile & Mitchell, 2005) , so the ability of a subset of the 23 BHT inhibitors to block biofilm formation was tested.
Inhibition of in vitro biofilm formation by BHT inhibitors
An adaptation of an established in vitro biofilm formation assay was used (Agarwal et al., 2008; Chandra et al., 2008) . This assay involved growing C. albicans cells in hyphalinducing Spider medium in individual wells of 48-well polystyrene microplates over a 48 h time period. Using this assay, it was confirmed that wild-type laboratory cells (strain BWP17) could form robust biofilms at 37 u C (Fig. 1) , and cells that contained a deletion of the Bcr1 transcription factor (strain CJN459) were defective in biofilm formation, as previously shown (Nobile & Mitchell, 2005; Nobile et al., 2006) . In addition, certain C. albicans strains were only able to form partial biofilms, as determined by visual inspection (Fig. 1) ; these partial biofilms were not a result of slow growth of the cells, as all the C. albicans strains tested had similar growth rates in both liquid complex media and hyphal-inducing Spider media (data not shown).
Of the 17 BHT inhibitors tested, only buhytrinA, ETYA and CGP-37157 were able to inhibit biofilm formation of the laboratory wild-type strain (Table 2 , Fig. 2 ). It should be noted that the BHT inhibitors were incubated with the cells for the duration of the 48 h incubation, so the molecules could be inhibiting the initial adherence of cells to the polystyrene microplates or the subsequent maturation of the biofilms. BuhytrinA (renamed from molecule 5762974; Toenjes et al., 2005) is a novel molecule with no known target within C. albicans or mammalian cells, although it does inhibit endocytosis as well as the BHT in C. albicans (Toenjes et al., 2005) . ETYA (5,8,11,14-eicosatetraynoic acid) is an inhibitor of mammalian lipooxygenases, which play a role in eicosanoid biosynthesis. C. albicans cells produce a variety of eicosanoids, which may regulate cell growth, morphogenesis, biofilm formation and virulence (Noverr et al., 2003; Alem & Douglas, 2005 ), but C. albicans does not have any recognizable lipooxygenases in its annotated genome sequence, so it remains to be determined whether ETYA is inhibiting the BHT and biofilm formation by inhibiting eicosanoid synthesis. CGP-37157 is known to affect calcium homeostasis through regulating intracellular calcium levels (Cox et al., 1993) . It is unclear why the other 14 BHT inhibitors were unable to block biofilm formation, but it was not due to a loss of molecule activity over the 48 h time period because these molecules could still block the BHT in liquid Spider medium over a similar 48 h time period (data not shown). It is possible that the signalling pathways affected by the 14 BHT inhibitors are not involved in regulating biofilm formation, so determining the targets of these BHT inhibitors will be critical in deciphering this unexpected result.
Hyphae formation and biofilm formation of clinical C. albicans isolates
Twenty-eight C. albicans clinical isolates were obtained from the Fletcher Allen Health Center Microbiology Laboratory to determine whether clinical strains from different patients responded to carbon starvation Spider medium similarly to laboratory strains. Interestingly, the clinical isolates varied in their ability to form hyphae in response to carbon starvation (Table 1 ). The laboratory wild-type strain BWP17 formed~80 % hyphae after 6 h at 37 u C in Spider medium. The clinical isolates varied from 1-2 % hyphae formation (Ca-114, Ca-123, Ca-141) up tõ 74 % (Ca-127). This varying ability to form hyphae in Spider medium was not the result of differing growth rates, as all the clinical isolates were comparable in their growth rates in defined YNB media (data not shown). It is unclear why the clinical isolates varied dramatically in their ability to form hyphae in response to carbon starvation, but it is possible that the clinical isolates have differences in the signalling pathways that respond to carbon availability.
It is thought that there is a direct correlation between hyphae formation and mature biofilm formation (Nobile & Mitchell, 2005) . To test this correlation with the clinical isolates, the in vitro biofilm assay was performed with the 28 strains ( Table 1) . As with the BHT assay, the clinical isolates varied in their ability to form biofilms after 48 h incubation at 37 u C. Eleven of the isolates formed robust biofilms comparable to biofilms formed by the laboratory strain BWP17, whereas 12 isolates were only able to form partial biofilms after 48 h (Table 1 , Fig. 1 ). Interestingly, five of the isolates were incapable of forming a biofilm.
When hyphae formation was correlated with biofilm formation (Table 1) , it was clear that there was not a direct correlation between these two processes. For instance, of the clinical isolates that could not form biofilms, isolates Ca-141 and Ca-136 formed between 1 and 5 % hyphae in the BHT assay, isolate Ca-138 formed~16 % hyphae, and isolates Ca-111 and Ca-131 formed between 34 and 40 % hyphae (Table 1) . Therefore, the ability of cells to form hyphae does not indicate that they will be able to form biofilms under similar growth conditions. Also, isolates Ca-114 and Ca-123 only formed 1-2 % hyphae in the BHT assay but were still able to form a partial biofilm, whereas isolates Ca-110, Ca-113, Ca-130, Ca-133 and Ca-134 formed~40 % hyphae but were only able to form partial biofilms. Even the clinical isolates that formed robust biofilms varied in their ability to form hyphae from~10 % to The indicated BHT inhibitors (100 mM final concentration) were incubated with the wild-type strain BWP17 in microplate wells as in Fig. 1 . Photographs of each well were obtained and the molecules were classified as either inhibitors (+) or non-inhibitors (2) of biofilm formation.
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75 %. It is clear from these studies that there is not a direct correlation between hyphae formation and biofilm formation in response to carbon starvation in these clinical isolates, suggesting that the signalling pathways that activate the BHT and biofilm formation under these growth conditions are not the same.
The ability of buhytrinA, ETYA and CGP-37157 to inhibit biofilm formation of the 11 clinical isolates that formed robust biofilms was tested (Table 3) . Again, the three BHT inhibitors varied in their ability to inhibit the clinical isolates. ETYA was the most efficacious, inhibiting biofilm formation of 100 % of the clinical isolates. CGP-37157 could inhibit 8 of the 11 isolates (73 %), whereas buhytrinA was only able to inhibit one of the isolates, Ca-120. BuhytrinA, ETYA and CGP-37157 were able to block the BHT of all the clinical isolates (data not shown), so the inability of buhytrinA and CGP-37157 to inhibit biofilm formation of the clinical isolates was not due to an inability to block the BHT. The molecular basis for these differences in biofilm inhibition is unknown but may be associated with the nature of the targets for these three inhibitors. ETYA and CGP-37157 may inhibit cellular processes, i.e. eicosanoid synthesis and calcium homeostasis, respectively, that are active in most C. albicans cells, whereas buhytrinA may inhibit a specific signalling pathway that is either absent or inactive in many clinical C. albicans isolates.
Determination of the subcellular targets for these BHT inhibitors should help explain these discrepancies.
Multiple studies have indicated that clinical isolates of C. albicans have varied abilities to respond to different growth media to form hyphae and to form biofilms, and that this variability is not associated with specific host conditions or characteristics (Shin et al., 2002; Gokce et al., 2007; Jain et al., 2007) . Our data also reflect this variability in both hyphae formation (1-80 %) and in the ability to form mature biofilms on abiotic surfaces (39 % of clinical isolates). The observation that 39 % of the clinical isolates were capable of forming biofilms in response to carbon limitation (i.e. growth on Spider medium) is somewhat high compared to the 8-12 % biofilm formation of other clinical isolates on other growth media (Shin et al., 2002; Gokce et al., 2007) , reinforcing the notion that growth medium, as well as strain differences, does play a role in biofilm formation (Jain et al., 2007) . It is clear that small molecules that inhibit the BHT and biofilm formation in wild-type laboratory strains can have very different effects against clinical C. albicans isolates. This observation should be taken into consideration when developing new antifungal therapeutics in the future. Patient information for the clinical C. albicans isolates was purposefully not obtained as it would not have affected the initial interpretation of the data. Since we have observed important differences between the clinical isolates with respect to hyphae formation and sensitivity to BHT inhibitors, future studies will factor in patient information and the body site of C. albicans isolation to see whether there is a correlation between patient disease states and characteristics of the C. albicans cells isolated from these patients. Table 3 . Ability of buhytrinA, ETYA and CGP-37157 to inhibit biofilm formation of the 11 clinical isolates that formed robust biofilms
The clinical C. albicans isolates that were capable of forming biofilms (see Table 1 ) were incubated in Spider medium within microplate wells for 48 h at 37 u C. Small molecules that were capable of inhibiting wild-type BWP17 biofilm formation (see Table 2 ) were added at a final concentration of 100 mM. Molecules were classified as either inhibitors (+) or non-inhibitors (2) of biofilm formation as in Table 2 . Inhibitors of Candida albicans biofilm formation
